immatics biotechnologies GmbH (IMTXW) - Total Liabilities
Based on the latest financial reports, immatics biotechnologies GmbH (IMTXW) has total liabilities worth $105.09 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IMTXW cash generation efficiency to assess how effectively this company generates cash.
immatics biotechnologies GmbH - Total Liabilities Trend (2018–2024)
This chart illustrates how immatics biotechnologies GmbH's total liabilities have evolved over time, based on quarterly financial data. Check immatics biotechnologies GmbH asset resilience ratio to evaluate the company's liquid asset resilience ratio.
immatics biotechnologies GmbH Competitors by Total Liabilities
The table below lists competitors of immatics biotechnologies GmbH ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lexaria Bioscience Corp
NASDAQ:LEXXW
|
USA | $1.53 Million |
|
Aquis Exchange PLC
LSE:AQX
|
UK | GBX7.47 Million |
|
BriaCell Therapeutics Corp
NASDAQ:BCTXW
|
USA | $3.35 Million |
|
Ucommune International Ltd
NASDAQ:UKOMW
|
USA | $173.94 Million |
|
African Agriculture Holdings Inc.
NASDAQ:AAGR
|
USA | $41.77 Million |
|
Latch Inc
NASDAQ:LTCHW
|
USA | $125.30 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down immatics biotechnologies GmbH's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is immatics biotechnologies GmbH worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how immatics biotechnologies GmbH's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for immatics biotechnologies GmbH (2018–2024)
The table below shows the annual total liabilities of immatics biotechnologies GmbH from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $121.30 Million | -57.42% |
| 2023-12-31 | $284.88 Million | +46.35% |
| 2022-12-31 | $194.66 Million | +29.27% |
| 2021-12-31 | $150.58 Million | +0.13% |
| 2020-12-31 | $150.39 Million | -14.12% |
| 2019-12-31 | $175.11 Million | +148.42% |
| 2018-12-31 | $70.49 Million | -- |
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more